Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents
Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.
In a subanalysis of the ACCORD BP trial, intensive blood pressure treatment in T2DM patients receiving standard glycemic control was significantly associated with a decreased risk of CV events, including HF hospitalization.
A prospective study showed an inversed association between nut consumption and incidence of atrial fibrillation and heart failure in the Swedish population.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
Maintaining or changing to a healthy lifestyle after diabetes diagnosis is associated with a significantly lower risk CVD incidence and mortality.
ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels
ADA 2018 In long-term Danish Steno 2 study, interventions targeting complications were found to improve disease-free-life length, and costs were not higher than with conventional treatment.
BP responses to exercise are similar in treated–controlled, treated-uncontrolled, and untreated hypertensives but higher compared with normotensives.
Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension
Before publication later this year, a first look at the new 2018 ESC/ESH Guidelines of hypertension was presented. One of the key messages was the unchanged definition of hypertension of BP >140/90 mmHg.
CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.